# US 2026/0265350 A1 · Sars-cov2 antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265350 A1
- Document ID: US20260265350A1
- Status: Published application
- Kind: A1
- Application number: 19/678,395
- Filed: 2026-05-15
- Published: 2026-09-10
- Earliest claimed: 2024-07-01
- Assignees: Invivyd, Inc.
- Applicants: Invivyd, Inc.
- Inventors: Laura Walker; Anna Wec; Robert Allen; Brandyn West; Daniel Chupp
- Web page: https://patentgrep.com/patent/US20260265350A1

## CPC

- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61P 37/04: Immunostimulants
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61P 31/14: for RNA viruses
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

## Claims

### Claim 1

An isolated antibody, or antigen-binding fragment thereof, which specifically binds to the spike protein of a coronavirus (“CoV-S”), wherein said antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR1 comprising SEQ ID NO: 12, a VH CDR2 comprising SEQ ID NO: 14, and a VH CDR3 comprising SEQ ID NO: 16, and a light chain variable region (VL) comprising a VL CDR1 comprising SEQ ID NO: 22, a VL CDR2 comprising SEQ ID NO: 24, and a VL CDR3 comprising SEQ ID NO: 26.

### Claim 2 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the VH comprises SEQ ID NO: 19 and the VL comprises SEQ ID NO: 29.

### Claim 3 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the VH consists of SEQ ID NO: 19 and the VL consists of SEQ ID NO: 29.

### Claim 4 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the CoV-S is the spike protein of SARS-CoV (“SARS-CoV-S”) or the spike protein of SARS-CoV-2 (“SARS-CoV-2-S”).

### Claim 5 (depends on 4)

The isolated antibody, or antigen-binding fragment thereof, of claim 4, wherein SARS-CoV-S comprises a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1, and wherein SARS-CoV-2-S comprises a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:5.

### Claim 6 (depends on 4)

The isolated antibody, or antigen-binding fragment thereof, of claim 4, wherein the SARS-CoV-2-S is a B.1.1.7 variant, a B.1.351 variant, a B.1.1.28 variant, a B.1.429 variant, a P.1 variant, a B.1.617 variant, a B.1.617.2 variant, a C.37 variant, a 1.621 variant, a AY.1 variant, a 1.623 variant, a C.36 variant, a A.27 variant, a AV.1 variant, a B.1.1.482 variant, a B.1.1.523 variant, a B.1.427 variant, a AY.4 variant, a AY.11 variant, a D614G variant, a B.1.1.529/BA.1 variant, a BA.4/5 variant, a BA.4.6 variant, a BA.7 variant, a BQ.1 variant, a BQ.1.1 variant, a BA.2.75 variant, a BN.1 variant, a XBB variant, a XBB.1 variant, a XBB.1.5 variant, a BJ.1 variant, a BM.1.1.1 variant, a BA.2.3.20 variant, a BF.7 variant, a XBC variant, a CH.1.1 variant, a XBB.1.16 variant, a XBB.1.5.10 variant, a XBB.1.5.1 variant, a XBB.2.3 variant, a FL.1.5.1 variant, a XBB.1.5.CONV0817 variant, a XBB.1.5.70 variant, a BA.2.86 variant, a BA2.86 CONV1207 variant, a HV.1 variant, a HK.3 variant, a JN.1 variant, a JN.4 variant, a JD.1.1 variant, a BA.2 variant, a JN.1.11.1 variant, a GE.1.2.1 variant, a JN.1.13.1 variant, a KQ.1 variant, a KP.1.1 variant, a KP.3 variant, a KP.2 variant, a JN.1.50 variant, a KP.3.1.1 variant, a XEC variant, a LB.1 variant, a MV.1 variant, a LP.8.1 variant, a MC.10.2. variant, a LF.8 variant, a LP.8.1.2 variant, a FL.15.1.1 variant, or a LF.7.2.1 variant.

### Claim 7 (depends on 4)

The isolated antibody, or antigen-binding fragment thereof, of claim 4, wherein the antibody, or antigen-binding fragment thereof, cross-reacts with SARS-CoV-S and SARS-CoV-2-S.

### Claim 8 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the antibody, or antigen-binding fragment thereof, binds to CoV-S with a KD value of about 100 nM or lower.

### Claim 9 (depends on 4)

The isolated antibody, or antigen-binding fragment thereof, of claim 4, wherein the antibody, or antigen-binding fragment thereof, neutralizes SARS-CoV and/or SARS-CoV-2 with an IC50 of about 100 nM or lower.

### Claim 10 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the antibody, or antigen-binding fragment thereof, have a Tm of at least about 62-70° C., about 63-70° C., or about 64-70° C.

### Claim 11 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof of claim 1, wherein the antibody, or antigen-binding fragment thereof, have a Ton of at least about 56-70° C., about 57-70° C., or about 58-70° C.

### Claim 12 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof of claim 1, wherein the antibody, or antigen-binding fragment thereof, has a serum half-life of about 40-200 days, about 50-160 days, about 50-140 days, about 55-75 days, about 60-90 days, about 50-90 days, about 50-80 days, about 40-70 days, or about 60-80 days.

### Claim 13 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the antibody is human, humanized, primatized, chimeric, bispecific or multispecific.

### Claim 14 (depends on 1)

The isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the antigen-binding fragment thereof comprises a Fab, Fab2, or scFv.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, of claim 1, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 2)

A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, of claim 2, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 3)

A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, of claim 3, and a pharmaceutically acceptable carrier.

### Claim 18

A method of treating or preventing infection by SARS-CoV, SARS-CoV-2, and/or another coronavirus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, which specifically binds to a spike protein of the coronavirus,
wherein the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (VH) comprising a VH CDR1 comprising SEQ ID NO: 12, a VH CDR2 comprising SEQ ID NO: 14, and a VH CDR3 comprising SEQ ID NO: 16, and a light chain variable region (VL) comprising a VL CDR1 comprising SEQ ID NO: 22, a VL CDR2 comprising SEQ ID NO: 24, and a VL CDR3 comprising SEQ ID NO: 26,
thereby treating or preventing infection by SARS-CoV, SARS-CoV-2, and/or another coronavirus in the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the VH comprises SEQ ID NO: 19 and the VL comprises SEQ ID NO: 29.

### Claim 20 (depends on 18)

The method of claim 18, wherein the VH consists of SEQ ID NO: 19 and the VL consists of SEQ ID NO: 29.

### Claim 21 (depends on 18)

The method of claim 18, wherein the subject is a human subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject is an adult, or an adolescent at least 12 years of age or older and weighting at least 40 kg.

### Claim 23 (depends on 18)

The method of claim 18, wherein the subject is immunocompetent.

### Claim 24 (depends on 18)

The method of claim 18, wherein the subject is immunocompromised, or the subject has at least one risk factor which renders them more prone to a poor clinical outcome and/or progression to severe infection.

### Claim 25 (depends on 24)

The method of claim 24, wherein the at least one risk factor is one or more of (i) an old age such as over 55, 60 or 65 years old, (ii) diabetes, (iii) a chronic respiratory condition such as asthma, bronchiectasis, cystic fibrosis, another fibrotic condition, chronic obstructive pulmonary disease (COPD), damaged or scarred lung tissue, pulmonary embolism or pulmonary hypertension, (iv) obesity, (iv) hypertension, (v) a cardiac or cardiovascular condition, such as heart defects or abnormalities, heart failure, coronary artery disease, cardiomyopathies, or hypertension, (vi) a chronic inflammatory or autoimmune condition such as lupus and multiple sclerosis, (vii) an immunocompromised status which may be caused by cancer, undergoing chemotherapy, smoking, bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV infection or AIDS, or prolonged use of corticosteroids or other immunosuppressive medications, (viii) cerebrovascular disease or stroke, (ix) chronic kidney disease, (x) chronic liver disease, such as alcohol-related liver disease, non-alcoholic fatty liver disease, autoimmune hepatitis, or cirrhosis, (xi) Down syndrome, (xii) hemoglobin blood disorders, such as sickle cell disease and thalassemia, and (xiii) neurologic conditions such as dementia or Parkinson's disease.

### Claim 26 (depends on 18)

The method of claim 18, wherein the antibody, or antigen-binding fragment thereof, is administered intravenously, subcutaneously, or intramuscularly.

### Claim 27 (depends on 18)

The method of claim 18, wherein the antibody, or antigen-binding fragment thereof, is administered at a dose of about 250 mg to about 1000 mg intramuscularly.

### Claim 28 (depends on 18)

The method of claim 18, wherein the antibody, or antigen-binding fragment thereof, is administered at a dose of about 1500 mg to about 4500 mg intravenously.

### Claim 29 (depends on 18)

The method of claim 18, wherein the antibody, or antigen-binding fragment thereof, is administered at a dose of about 250 mg to about 1250 mg subcutaneously.

### Claim 30 (depends on 18)

The method of claim 18, wherein the antibody, or antigen-binding fragment thereof, is administered once, or is administered weekly, monthly, every two months, every three months, every six months, or every year.
